Company intelligence / Profile preview

Stemtech

Ownership: Private
Employees: ~184
Development stage: Other

Overview

Stemtech markets plant-based nutritional supplements designed to enhance the body’s natural renewal system by supporting the release and activity of adult stem cells. Their flagship RCM System includes products like Stemrelease3™, which have been clinically tested for their ability to increase circulating adult stem cells. The company has expanded into skin care and is preparing to launch pet health products in 2025. No pharmaceutical clinical trial data is available as these are not regulated drug products.

Therapeutic areas: Other
Modalities: Nutritional supplementPlant-based therapy
Industry: Food & Nutrition

Beyond the preview

Go deeper on Stemtech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Stemtech.

Explore the full profile